Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging

Phase 2Not Yet RecruitingNCT06568783

Farshad Moradi21 enrolled

Overview

This study proposes the use of a PET isotope, \[18F\]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory Dermatomyostitis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Refractory Dermatomyostitis

Interventions

[18F]-FAPI-74DRUG

\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with suspected dermatomyositis. 2. Patient must be \> 18 years old. 3. Be willing and able to provide written informed consent for the trial. Exclusion Criteria: 1. Women who are pregnant or potentially pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women. 2. Contraindication to MRI or inability to lie flat for 30 min 3. Any serious medical condition that in the opinion of principal investigator could pose significant risk of harm or injury to the patient if they participate in the study

Locations (1)

Stanford University

Stanford, California, United States

Outcomes

Primary Outcomes

Rate of [18F]-FAPI-74 uptake.

write the outcome title, how it will be measured.

Time frame: up to 1 hour

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.